Updated:
Medpace Holdings
Medpace provides outsourced Phase I–IV clinical development services, including trial management, site start-up, recruitment and monitoring.
Overview
Medpace Holdings provides outsourced clinical development services to biotechnology, pharmaceutical and medical device companies. As a contract research organization, it supports Phase I through Phase IV studies across multiple therapeutic areas, including oncology, metabolic disease, cardiology and central nervous system disorders. Its services include study planning, clinical trial management, site selection and start-up, patient recruitment and clinical monitoring. For fiscal 2025, ended December 31, 2025, it reported revenue of approximately $2.530 billion and total assets of approximately $1.975 billion at year-end.
Company overview
- Legal name
- Medpace Holdings, Inc.
- Classification
- Public company
- Incorporated in
- Delaware
- SEC CIK
- 0001668397
- LEI
- 549300H8TYEUVTW14A54
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $2.5B | $451.1M | $2.0B | $497.0M | $713.2M | |
| FY2024USD | $2.1B | $404.4M | $2.1B | $669.4M | $608.8M | |
| FY2023USD | $1.9B | $282.8M | $1.7B | $245.4M | $433.4M | |
| FY2022USD | $1.5B | $245.4M | $1.4B | $28.3M | $388.1M |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Medpace Holdings in Altss
Track this company’s investors, transactions and relationships in Altss.